Pregnancy Outcome in Women Treated With Adalimumab for the Treatment of Rheumatoid Arthritis: An Update on the OTIS Autoimmune Diseases in Pregnancy Project
Notice bibliographique
Résumé
Introduction: To investigate pregnancy outcomes in women who received adalimumab (ADA) to treat rheumatoid arthritis (RA) during pregnancy. Methods: The OTIS collaborative research group conducted a prospective cohort study in the U.S. and Canada, 2004-2013, comparing pregnancy outcomes in women with RA treated with ADA to women with RA not treated with ADA. Participants may have been treated with another disease-modifying antirheumatic drug or steroid but not methotrexate. An additional comparison group included women without any autoimmune disease. Participants enrolled <19 weeks gestation and were followed by telephone interviews and medical record review. A subset of infants received a dysmorphological examination by a study physician. Outcomes were compared using regression or survival methods with adjustment for confounders. Results: Seventy-four ADA-exposed, 80 disease-matched and 218 non-diseased women were enrolled. Women in the ADA group had at least 1 dose in the first trimester; ˜43% used ADA in all trimesters. Disease severity was similar between the two diseased groups. The rates of major defects in the exposed, disease-matched, and non-diseased comparison groups were 5.6%, 7.8%, and 5.5% respectively. There was no significant difference in the rate of major malformations among live births in the ADA vs. disease-matched group (adjusted relative risk 1.14, 95% confidence interval [CI] 0.26, 4.93). Among those who received the dysmorphological examination, there were no differences in number with ≥3 minor malformations, and no specific pattern was identified. There was no significant difference in the risk of spontaneous abortion in the ADA vs. disease-matched groups (adjusted hazard ratio 1.96, 95% CI 0.47, 8.26); the rate was elevated in comparison to the non-diseased group (adjusted hazard ratio 3.79, 95% CI 1.01, 14.23), although the number of events was small. Rates of preterm delivery and small for gestational age were similar across groups. Conclusion: Pregnant women with RA treated with ADA in the first trimester compared to women with the same condition do not appear to be at increased risk of the adverse pregnancy outcomes evaluated. Although the sample size is small, these results are reassuring to pregnant women with RA who require treatment with ADA. AbbVie provided funding for this study and participated in the study design. AbbVie did not participate in study conduct, analysis, and interpretation of data. AbbVie had the opportunity to review and comment on the publication. All authors independently analyzed and interpreted the data, and authors maintained full control over the content of the publication. Disclosure - Research Grant Funding: Bristol Myers Squibb, La Roche, Genentech, CSL, Novartis, Amgen, Celgene, GSK, UCB, Eli, Protein Sciences, Abbott, TIS, Norvartis, Janseen, Sanofi Aventis, Pfizer. This research was supported by an industry grant from This research was supported by a grant from AbbVie Inc.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,006 | 0,009 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,001 |
| Bibliométrie | 0,004 | 0,004 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,001 | 0,001 |
| Science ouverte | 0,001 | 0,001 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».